Active	Status	Sponsor type	Region	Phase	Filter
7 Active 4 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hall, Michelle
ReSTART, NCT05459259: Physiotherapy for Arthrofibrosis Following Knee Replacement.	Recruiting	N/A	145	Europe	Interviews and Delphi Survey	University of Nottingham, King's College London, National Institute for Health Research, United Kingdom	Arthroplasty Complications, Fibrosis, Knee Joint Contracture	08/23	08/23
Dueno, Otto
NCT04109950 / 2019-000696-16: A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia	Terminated	3	452	Europe, US, RoW	SEP-363856	Otsuka Pharmaceutical Development & Commercialization, Inc., Sunovion Pharmaceuticals Inc.	Schizophrenia	11/23	11/23
OUTLAST, NCT05034874: Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200	Terminated	2	61	US	IXT-m200, Placebo	InterveXion Therapeutics, LLC, National Institute on Drug Abuse (NIDA)	Methamphetamine-dependence, Methamphetamine Abuse	09/23	11/23
NCT04948307: OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder	Completed	N/A	437	US	OXD01 digital therapy, Standard of Care	Orexo AB	Opioid-use Disorder	04/23	05/23
Folkerth, Steven
NCT04785638: An Open-label Safety and Pharmacokinetic Study of INL-001 in Adults Following Various Open Soft-Tissue Surgeries	Completed	3	100	US	INL-001 (bupivacaine hydrochloride) implant, XARACOLL (bupivacaine hydrochloride) Implant	Innocoll	Pain, Postoperative, Hernia, Ventral, Abdominoplasty, Hysterectomy, Colectomy, Reduction Mammoplasty	01/23	01/23
NCT04971109: Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Day	Completed	3	467	US	TPOXX, tecovirimat, ST-246, TPOXX Placebo, Placebo	SIGA Technologies, United States Department of Defense	Smallpox	05/23	05/23
Vernon, Rebecca
NCT06179108: Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia	Recruiting	2	350	US	LB-102	LB Pharmaceuticals Inc.	Schizophrenia	10/24	01/25